Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.41 |
| ▸ | CKS1B | P61024 | 1/20 | 0.37 |
| ▸ | SKP1 | P63208 | 1/20 | 0.37 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | YAP1 | P46937 | 3/20 | 0.36 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.36 |
| ▸ | KLK7 | P49862 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | F10 | P00742 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1772065 | 0.94 | HRH3 (0.38) | GPR119CKS1BSKP1SKP2MAPT | |
| SCHEMBL1773978 | 0.91 | GPR119 (0.41) | GPR119CKS1BSKP1SKP2LMNA | |
| SCHEMBL1773414 | 0.89 | YAP1 (0.47) | GPR119LMNATP53MAPTYAP1 | |
| SCHEMBL17029520 | 0.89 | YAP1 (0.36) | LMNAYAP1PRMT5KLK7HPGD | |
| SCHEMBL12602054 | 0.89 | ME3 (0.39) | GPR119CKS1BSKP1SKP2MAPT | |
| Hydrochloric Acid SCHEMBL1773711 | 0.88 | ME3 (0.39) | GPR119CKS1BSKP1SKP2MAPT | |
| SCHEMBL1773015 | 0.88 | F10 (0.39) | LMNAMAPTF10CHRM4 | |
| SCHEMBL1773046 | 0.88 | YAP1 (0.44) | GPR119YAP1PRMT5GAA | |
| SCHEMBL1771803 | 0.87 | YAP1 (0.40) | LMNATP53MAPTYAP1PRMT5 | |
| SCHEMBL12782961 | 0.87 | GPR119 (0.41) | GPR119CKS1BSKP1SKP2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110112103-A1 | 5-HYDROXYPYRIMIDINE-4-CARBOXAMIDE COMPOUND | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-05-12 | — | — | US | disclosed |
| US-20110112103-A1 | 5-HYDROXYPYRIMIDINE-4-CARBOXAMIDE COMPOUND | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-05-12 | — | — | US | disclosed |
| US-20110112103-A1 | 5-HYDROXYPYRIMIDINE-4-CARBOXAMIDE COMPOUND | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112103-A1 | 5-HYDROXYPYRIMIDINE-4-CARBOXAMIDE COMPOUND | EPOR, CBR1, CBR3 | GPR119 488/4885CKS1B 1138/4885SKP1 1646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.